[Use of specific intravenous varicella-zoster immunoglobulins in the prevention of varicella in immunocompromised children: clinical and serological evaluation].
Macchia
P
P
Favre
C
C
Nardi
M
M
Consolini
R
R
Conaldi
P G
PG
Bendinelli
M
M
D000293:Adolescent; D000914:Antibodies, Viral / Q000032:analysis; D002644:Chickenpox / Q000517:prevention & control*; D002648:Child; D002675:Child, Preschool; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D014645:Herpesvirus 3, Human / Q000276:immunology*; D006801:Humans; D007106:Immune Sera; D007116:Immunization, Passive; D007153:Immunologic Deficiency Syndromes / Q000150:complications*; D007223:Infant; D007945:Leukemia, Lymphoid / Q000150:complications*; D015470:Leukemia, Myeloid, Acute / Q000150:complications; D008228:Lymphoma, Non-Hodgkin / Q000150:complications; D008297:Male; D012307:Risk Factors
D000914:Antibodies, Viral; D007106:Immune Sera; C030799:varicella-zoster immune globulin
Uso delle immunoglobuline specifiche anti varicella Zoster (VZIG) per via endovenosa nella profilassi della varicella in bambini immunocompromessi: valutazione clinica e sierologica.